Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ruxolitinib Versus Allogeneic Stem Cell Transplantation for Patients With Myelofibrosis According to Donor Availability: A Prospective Phase II Trial (MMM 02 Study)

NCT03333187 is registered in ClinicalTrials.gov with Universitätsklinikum Hamburg-Eppendorf as lead sponsor.

NCT NCT03333187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03333187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ruxolitinib Versus Allogeneic Stem Cell Transplantation for Patients With Myelofibrosis According to Donor Availability: A Prospective Phase II Trial (MMM 02 Study)
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 21, 2016
Completion date
October 7, 2025
Enrollment
87 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

bone marrow fibrosis